Adaptative immunotherapy of advanced solid tumors

C. Semino, G. Ferlazzo, G. B. Ratto, G. Melioli

Research output: Contribution to journalArticlepeer-review


Adoptive immunotherapy (AI) of cancer, based upon injection of in vitro manipulated autologous lymphocytes is still in an experimental phase. Based on strong experimental and pre-clinical rationale, our group started different clinical trials of AI in early 1990, and a number of patients with solid tumors (melanoma, kidney carcinoma, non-small-cell lung cancer, mesothelioma, neoplastic pleural effusion, and liver cancer) were treated with either locoregional or systemic adoptive immunotherapy using both LAK and TIL cells in combination with s.c. rIL-2. The surgery/AI combination resulted. in good clinical results, characterized by enhanced. survival and long lasting disease free periods in a significant number of patients. Nevertheless, at present, new preclinical evidences and strategies are needed to enhance the efficacy of the adoptive immunotherapy approach of solid tumor treatment.

Original languageEnglish
Pages (from-to)311-317
Number of pages7
JournalMinerva Biotecnologica
Issue number4
Publication statusPublished - Dec 1999


  • Carcinoma, non-small-cell lung/therapy Immunotherapy, adoptive
  • Interleukin-2/administration and dosage
  • Lymphocytes, tumor-infiltrating, immunology

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'Adaptative immunotherapy of advanced solid tumors'. Together they form a unique fingerprint.

Cite this